Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Acute Graft-versus-host disease(aGVDH) after allogeneic hematopoietic stem cell
transplantation is one of the meaningful issues in aspect of patient's recovery and survival.
in recent years, the understanding of the pathology of GVHD is much important to prevent or
treat aGVHD. additionally, (oral) mucositis is one of the problems in patients with high dose
chemotherapy, and mucositis by high-dose chemotherapy is related to HMGB-1 as proinflamtory
cytokines. HMGB1 is a nuclear protein acts as a transcription factor, but, if it was released
to the outside of cells by damaged cell or necrotic tissues, it works as cytokines for
promoter of inflammation and cancers. at this point, there are no reported articles about
correlation of HMGB1 and aGVHD in human. recently, we have seen excessive secretion of serum
HMGB1 in mouse model, then base on this results, we will check correlation of HMGB1 and
aGVHD/ oral mucositis in human.